Bacillus Calmette–Guérin
Bill of Testing
CompanyCore Data Sheet
Clinical Development Plan
Clinical
Chemistry, Manufacturing, and Controls
Cost of Goods
Correlates of Protection
Critical Process Parameters
Critical Quality Attributes
Clinical Research Centres
Clinical Safety Report
Clinical Trial Application
Clinical Trial Material
Drug product
Drug substance
Ethics Committee
Evidence Considerations for Vaccine Policy
European Medicines Agency
First In Human
Global Alliance for Vaccines and Immunisation
Genetically Modified Organism
Good Manufacturing Practice
Good Participatory Practice
Health Economics and Outcome Research
Investigational Brochure
Intellectual Property
Key Opinion Leader
Lipid Nano Particle
Market Authorization Application
Material transfer agreement
Mycobacterium tuberculosis
Non Human Primate
National Immunization Programs
National Regulatory Authority
OfficialMedicines Control Laboratory
Product Development Plan
Prinicipal Investigator
People Living With HIV
Project management
Proof of Concept
Prevention of Disease
Prevention of Infection
Prevention of Recurrence
Preferred Product Characteristics
Quality Control
Quality Management System
Regulatory Authority
Risk Management Plan
Strategic Advisory Group of Experts on Immunization
Stage Gate Criteria
Tuberculosis
Mtb antigen-based skin test
Target Product Profile
Vaccine Investment Strategy